Pediatric catheter interventions: A year in review 2004-2005

Current Opinion in Pediatrics

Volumn 17, Issue 5, 2005, Pages 568-573

  Patel, Hitendra T ^a   Hijazi, Ziyad M ^b,c  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Congenital cardiac defects; Fetal interventions; Hybrid surgery; Transcatheter interventions

Indexed keywords

AORTA VALVE REPLACEMENT; BIOPROSTHESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGENITAL HEART DISEASE; HEART ATRIUM SEPTUM DEFECT; HEART BLOCK; HEART CATHETERIZATION; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VALVE REPLACEMENT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; INCIDENCE; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS;

ADULT; AORTIC VALVE; CHILD; FETAL HEART; HEART CATHETERIZATION; HEART SEPTAL DEFECTS, ATRIAL; HEART SEPTAL DEFECTS, VENTRICULAR; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INFANT, NEWBORN; PULMONARY VALVE;

EID: 26044446462     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000172813.56766.52     Document Type: Review

References (33)

1. Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum type atrial septal defect closure using Amplatzer septal occluders. J Am Coll Cardiol 2005; 45:505-507. The authors present 4.67-9-year follow-up data on 151 patients who underwent closure of ASD with the ASO; 100% closure was seen at 3-year follow-up. No deaths or new complications were noted.
2. Yew G, Wilson NJ. Transcatheter atrial septal defect closure with the Amplatzer septal occluder: five-year follow-up. Catheter Cardiovasc Interv 2005; 64: 193-196. This study reports on 3-5.7-year follow-up data on 25 patients who underwent closure of ASD with the ASO. There was complete closure in all with no new long-term complications.
3. Butera G, Carminati M, Chessa M, et al. CardioSEAL/STARflex versus Amplatzer devices for percutaneous closure of small to moderate (up to 18 mm) atrial septal defects. Am Heart J 2004; 148:507-510. This is a performance comparison of the CardioSEAL and STARflex (n = 121) versus Amplatzer septal occluder (n = 153) devices for percutaneous closure of small to moderate (up to 18 mm) atrial septal defects in 274 consecutive patients. Both devices were effective but the ASO was easier to use with a higher complete closure rate.
4. Baykut D, Doerge SE, Grapow M, et al. Late perforation of the aortic root by an atrial septal defect occlusion device. Ann Thorac Surg 2005; 79:e28. This is a case report of late atrial erosion caused by a septal occluder.
5. Preventza O, Sampath-Kumar S, Wasnick J, Gold JP. Late cardiac perforation following transcatheter atrial septal defect closure. Ann Thorac Surg 2004; 77:1435-1437. This is a case report of late atrial erosion caused by a septal occluder.
6. Amin Z, Hijazi ZM, Bass JL, et al. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv 2004; 63:496-502. The authors give an expert panel review of all available data on 28 cases of atrial perforation caused by Amplatzer devices reported to the manufacturer. These patients were compared to patients enrolled in the U.S. multicenter pivotal study that resulted in the approval of the device. The overall risk of erosion is very small, 0.1%, and erosions seemed limited to defects with a deficient anterior superior rim and many of the cases involved the use of significantly oversized devices. Recommendations on sizing and on following patients were also made.
7. Divekar A, Gaamangwe T, Shaikh N, et al. Cardiac perforation after device closure of atrial septal defects with the Amplatzer Septal Occluder. J Am Coll Cardiol 2005; 45:1213-1218. This is a case report and review of 29 cases of potential cardiac perforation as reported to the FDA database. Information was accessed from the Manufacturer and User Facility Device Experience Database.
8. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1000 consecutive patients. J Am Coll Cardiol 2004; 43:302-9. The authors report on a large patient study to assess the incidence of thrombus formation in patients who underwent device closure of atrial septal communication (ASD and PFO) by TEE at 1 and 6 months. Data on six different devices was presented with the HELEX and ASO devices having minimal or no risk of thrombosis.
9. Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004; 93:426-431. Thrombus formation by TEE at 1 month after device closure of atrial septal defect was found on 22% of the CardioSEAL device cases (n = 23) and in none of the ASO device cases (n = 27).
10. Suda K, Raboisson MJ, Piette E, et al. Reversible atrioventricular block associated with closure of atrial septal defects using the Amplatzer device. J Am Coll Cardiol 2004; 43:1677-1682. Large ASO devices were associated with higher incidence of atrioventricular node dysfunction. In this study, atrioventricular node dysfunction was transient and recovered within 6 months in most cases even in patients who developed complete heart block.
11. Knauth AL, Lock JE, Perry SB, et al. Transcatheter device closure of congenital and postoperative residual ventricular septal defects. Circulation 2004; 110:501-507. This is a report of a single-institution experience over a 13-year period with device closure of VSD, non-repaired congenital and residual postoperative, using the Clamshell, CardioSEAL, and STARFlex devices. This is a comprehensive outcome data study on transcatheter closure of VSD.
12. Holzer R, Blazer D, Cao QL, et al. Device closure of muscular ventricular septal defects using the Amplatzer muscular ventricular septal defect occluder: immediate and mid-term results of a U.S. registry. J Am Coll Cardiol 2004; 43: 1257-1263. Seventy-five patients underwent 83 procedures to close muscular VSDs using the Amplatzer muscular VSD occluder device data to a median follow up of 211 days; 92% closure rate was reported at 6 months. Major complications occurred in eight patients with two deaths. The data confirmed that muscular VSDs could be closed successfully using the Amplatzer device.
13. Arora R, Trehan V, Thakur AK, et al. Transcatheter closure of muscular ventricular septal defect. J Interv Cardiol 2004; 17:109-115. The authors present a report of 50 patients who underwent closure of muscular VSD, Rashkind umbrella device in 2 and the rest of the devices were Amplatzer VSD occluders. Complete closure in all with no complications noted at follow up. One patient had transient complete heart block.
14. Thanopoulos BD, Rigby ML. Outcome of transcatheter closure of muscular ventricular septal defects with the Amplatzer ventricular septal defect occluder. Heart 2005; 91:513-516. This is a report of 30 patients with single muscular VSD who underwent closure with the Amplatzer VSD occluder device. Complete closure occurred in 28 patients and 1 patient developed left bundle branch block that progressed to complete heart block at 1 year.
15. Hijazi ZM, Hakim F, Haweleh AA, et al. Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: initial clinical experience. Catheter Cardiovasc Interv 2002; 56: 508-515.
16. Thanopoulos BD, Tsaousis GS, Karanasios E, et al. Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer asymmetric ventricular septal defect occluder: preliminary experience in children. Heart 2003; 89:918-922.
17. Bass JL, Kalra GS, Arora R, et al. Initial human experience with the Amplatzer perimembranous ventricular septal occluder device. Catheter Cardiovasc Interv 2003; 58:238-245.
18. Pedra CA, Pedra SR, Esteves CA, et al. Percutaneous closure of perimembranous ventricular septal defects with the Amplatzer device: technical and morphological considerations. Catheter Cardiovasc Interv 2004; 61: 403-410. Ten patients were followed after device closure of perimembranous VSDs using the Amplatzer device with complete closure in nine patients with no major complications. VSD diameter ranged from 3-17 mm.
19. Pawelec-Wojtalik M, Masura J, Siwinska A, et al. Transcatheter closure of perimembranous ventricular septal defect using an Amplatzer occluder-early results. Kardiol Pol 2004; 61:31-40. This is a study of nine patients with conoventricular VSD and complete closure in all patients with the Amplatzer perimembranous VSD device with no major complications.
20. Akintuerk H, Michel-Behnke I, Valeske K, et al. Stenting of the arterial duct and banding of the pulmonary arteries: basis for combined Norwood stage 1 and 11 repair in hypoplastic left heart. Circulation 2002; 105: 1099-1103.
21. Boucek MM, Mashburn C, Chan KC. Catheter-based interventional palliation for hypoplastic left heart syndrome. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2005; 8:72-77. The authors present of follow-up data in 40 infants who underwent initial transcatheter palliation for HLHS. Overall survival to second stage palliation or orthotopic heart transplant was 75%. Transcatheter-placed internal pulmonary artery bands were effective and did not lead to distortion of the pulmonary arteries requiring reconstruction at the second stage.
22. Galantowicz M, Cheatham JP. Fontan completion without surgery. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004; 7:48-55. This study outlined how standard surgical techniques could be modified to facilitate future transcatheter therapy. Transcatheter Fontan completion was reported in five patients.
23. Michel-Behnke I, Akintuerk H, Thul J, et al. Stent implantation in the ductus arteriosus for pulmonary blood supply in congenital heart disease. Catheter Cardiovasc Interv 2004; 61:242-252. This was a significant study as it assessed the outcome of ductal patency after stent placement in 21 patients. Ductal patency was maintained from 8-1130 days.
24. Bacha EA, Hijazi ZM, Cao QL, et al. New Therapeutic Avenues with Hybrid Pediatric Cardiac Surgery. Heart Surg Forum 2004; 7:33-40. This was a great study to illustrate how hybrid techniques could be of use in many different cardiac lesions to simplify and shorten the final surgical repair.
25. Bonhoeffer P, Boudjemline Y, Qureshi SA, et al. Percutaneous insertion of the pulmonary valve. J Am Coll Cardiol 2002; 39:1664-1669.
26. Boudjemline Y, Agnoletti G, Bonnet D, et al. Percutaneous pulmonary valve replacement in a large right ventricular outflow tract: an experimental study. J Am Coll Cardiol 2004; 43:1082-1087. The authors developed a method for transcatheter placement of a bioprosthetetic valve in the pulmonary position in an animal model with large pulmonary trunks. They describe the development of a stent with a central constriction that could be used to reduce the right ventricle outflow tract.
27. Boudjemline Y, Schievano S, Bonnet C, et al. Off-pump replacement of the pulmonary valve in large right ventricular outflow tracts: A hybrid approach. J Thorac Cardiovasc Surg 2005; 129:831-837. This was an animal study to develop a method for transcatheter placement of a bioprosthetic valve in the pulmonary position with large pulmonary trunks. In this study, the dilated pulmonary trunk was reduced in size by initial surgical placement of a pulmonary artery band.
28. Coats L, Tsang V, Khambadkone S, et al. The potential impact of percutaneous pulmonary valve stent implantation on right ventricular outflow tract re-intervention. Eur J Cardiothorac Surg 2005; 27:536-543. This study compared the performance of surgically placed RVOT valved conduits and percutaneously placed stent mounted bovine jugular venous valves. Freedom from re-operation at 1 year was 100% in the surgical group and 86% in the stent valve group. Re-intervention was for stenosis.
29. Boudjemline Y, Bonhoeffer P. Steps towards percutaneous aortic valve replacement. Circulation 2002; 105:775-778.
30. Cribier A, Eltchaninoff H, Tron C, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 2004; 43:698-703.
31. Vlahos AP, Lock JE, McElhinney DB, van der Vele ME. Hypoplastic left heart syndrome with intact or highly restrictive atrial septum: outcome after neonatal transcatheter atrial septectomy. Circulation 2004; 109:2326-2330.
32. Marshall AC, van der Velde ME, Tworetzky W, et al. Creation of an atrial septal defect in utero for fetuses with hypoplastic left heart syndrome and intact or highly restrictive atrial septum. Circulation 2004; 110:253-258. This is the first human study to present data on percutaneous atrial septostomy in the fetus. The selection process, technique, and outcome are described.
33. Tworetzky W, Wilkins-Haug L, Jennings RW, et al. Balloon dilation of severe aortic stenosis in the fetus: potential for prevention of hypoplastic left heart syndrome: candidate selection, technique, and results of successful intervention. Circulation 2004; 110:2125-2131. This is the first human study to present data on percutaneous balloon dilation of the aortic valve in the fetus. The selection process, technique, and outcome are described.